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Electronic Versus Faxed Prescriptions
Electronic prescriptions for Schedules II–VI are ac-
ceptable only if both the prescriber and pharmacy computer 
systems and software meet Drug Enforcement Administra-
tion (DEA) verification and authentication requirements. 
The transmission is considered secure since the data is 
being electronically exchanged between the prescriber and 
pharmacy computer systems.
If the prescriber’s software converts an electronically 
signed, computer-generated prescription into a computer-
generated fax, this would not be considered an electronic 
prescription. Similarly, electronically generated prescrip-
tions that have been printed are considered “paper-based” 
and require a manual, handwritten signature. 
Regardless of how the script was generated, if it arrives 
to the pharmacy as a fax, it is subject to the faxed prescrip-
tion rules.
A pharmacy may accept faxed prescriptions for Sched-
ule III-VI medications, provided that the prescription was 
manually signed prior to faxing. If it was not manually 
signed, it should be treated as an oral prescription, thereby 
requiring the pharmacist to verify with the prescriber before 
dispensing. 
As always, traditional paper prescriptions require 
manual, handwritten signatures. 
Please visit the following links for more information:
♦ www.mass.gov/eohhs/docs/dph/regs/105cmr721.pdf
♦ https://www.deadiversion.usdoj.gov/pubs/manuals/
pharm2/pharm_content.htm#9
♦ https: / /www.uspharmacist .com/CMSImages
Content/2011/9/Tech-RxT1.gif
Substance Use Disorder Assistance
A new program is now available for pharmacists, phar-
macy interns, and pharmacy technicians afflicted with 
substance use disorder (SUD) involving alcohol or drugs. 
The Pharmacy Substance Use Disorder (PSUD) Program 
was established as a result of a new law that allows the 
Massachusetts Board of Registration in Pharmacy to estab-
lish a voluntary, confidential, non-disciplinary rehabilita-
tion program to assist its licensees.
Individuals in the pharmacy profession and health care 
in general are at higher risk for an SUD. Studies published 
in the Journal of the American Pharmacists Association 
in 2017 have estimated that 7-25% of pharmacists are 
affected by this disorder. Currently, 46 states offer programs 
for pharmacy licensees, with anecdotal success rates of 
80-85%.
The program offered by the Board typically involves
a five-year monitoring program coordinated by PSUD 
Program Supervisor Ed Taglieri, MSM, NHA, RPh, with 
oversight and direction from the Rehabilitation Evalua-
tion Committee (REC). The program components include: 
abstinence from controlled substances (CS) and alcohol, 
random testing, individual treatment, peer support, re-
stricted and/or monitored practice, and regular self-help 
meetings. Periodic meetings with the REC are also part 
of the treatment program. Participation in the PSUD 
Program is confidential and non-disciplinary so long as 
the licensee complies with the terms of the rehabilitation 
program. Please note, however, that failure to comply with 
the requirements of the rehabilitation program may result 
in disciplinary action (including suspension) against the 
licensee.
Admissions and referrals can be made voluntarily or as 
a result of disciplinary concerns resulting from SUD in the 
workplace. For more information, contact Ed Taglieri at the 
Board at 617/973-0908 or edmund.taglieri@state.ma.us.
Technician Trainee Licensure
Recently revised regulation 247 Code of Massachusetts 
Regulation (CMR) 8.03 now requires all pharmacy 
technician trainees to be licensed by the Board. Effec-
tive April 6, 2018, no individual may work as a technician 
trainee without holding a valid pharmacy technician trainee 
license.
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drugs or press it into counterfeit prescription pills, often 
without users’ awareness, which leads to overdose inci-
dents, notes the 2017 NDTA. To access the 2017 NDTA, 
visit www.dea.gov/divisions/hq/2017/hq102317.shtml.
FDA Recognizes Eight European Drug 
Regulatory Authorities Capable of 
Conducting Inspections
FDA has determined it will recognize eight European 
drug regulatory authorities as capable of conducting 
inspections of manufacturing facilities that meet FDA 
requirements. The eight regulatory authorities found to be 
capable are those located in Austria, Croatia, France, Italy, 
Malta, Spain, Sweden, and the United Kingdom. This 
achievement marks an important milestone to successful 
implementation and operationalization of the amended 
Pharmaceutical Annex to the 1998 US-European Union 
(EU) Mutual Recognition Agreement, which enables US 
and EU regulators to utilize each other’s good manufactur-
ing practice inspections of pharmaceutical manufacturing 
facilities. “By partnering with these countries, we can 
create greater efficiencies and better fulfill our public 
health goals, relying on the expertise of our colleagues 
and refocusing our resources on inspections in higher risk 
countries,” said FDA Commissioner Scott Gottlieb, MD, 
in a news release located at www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm583057.htm. 
Incorrect Use of Insulin Pens at Home 
Can Cause Severe Hyperglycemia
The National Coordinating Council for Medication 
Error Reporting and Prevention has issued an alert on 
the incorrect use of insulin pens at home causing severe 
hyperglycemia in patients, including one reported fatal-
ity. The Institute for Safe Medication Practices National 
Medication Errors Reporting Program has received sev-
eral reports of patients who failed to remove the inner 
cover of standard insulin pen needles prior to admin-
istering insulin. In the latest such event, a patient with 
type 1 diabetes did not know to remove the standard needle 
cover and was unaware she was using the pen incorrectly 
and had not been receiving any of the insulin doses; the 
patient developed diabetic ketoacidosis as a result and 
died. 
Since insulin pens may differ between pens with 
automatic needle retraction devices and those with stan-
dard needle covers that require manual removal before 
administering insulin, it is imperative that removal of 
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FDA Requires Labeling Update on 
Opioid-Containing Cough and Cold 
Medicines
In January 2018, Food and Drug Administration (FDA) 
announced that the agency is requiring safety labeling 
changes to limit the use of prescription opioid cough 
and cold medicines containing codeine or hydrocodone 
in children younger than 18 years old because the seri-
ous risks of these medicines outweigh their potential 
benefits in this population. After safety labeling changes 
are made, these products will no longer be indicated for 
use to treat cough in any pediatric population and will 
be labeled for use only in adults aged 18 years and older. 
In addition, labeling for the medications will be updated 
with additional safety information for adult use. This up-
date will include an expanded Boxed Warning notifying 
consumers about the risks of misuse, abuse, addiction, 
overdose and death, and slowed or difficult breathing 
that can result from exposure to codeine or hydroco-
done. Additional information is available in FDA’s news 
release at www.fda.gov/NewsEvents/Newsroom/Press 
Announcements/ucm592109.htm.
Latest NDTA Shows Opioids Pose 
Significant Impact to Public Health
Drug Enforcement Administration (DEA) indicates a 
significant shift in the overall drug threat reported by law 
enforcement over the last 10 years with opioids (including 
controlled prescription drugs, fentanyl and other synthetic 
opioids, and heroin) reaching epidemic levels and impact-
ing significant portions of the United States. According 
to the 2017 National Drug Threat Assessment (NDTA) 
report, every year since 2001, controlled prescription 
drugs, specifically opioid analgesics, have been linked to 
the largest number of overdose deaths of any illicit drug 
class, outpacing those for cocaine and heroin combined. 
From 2007 to 2010, responses to the National Drug 
Threat Survey indicate cocaine was the greatest national 
drug threat, followed by a significant decline as the her-
oin threat increased between 2010 and 2016, eventually 
becoming the greatest national drug threat in 2015. 
Illicit fentanyl and other synthetic opioids, primarily 
sourced from China and Mexico and shipped directly to 
the US or trafficked overland via Mexico and Canada, 
are contributing factors in the current synthetic opioid 
overdose epidemic. Traffickers in the US usually mix 
fentanyl into heroin products and sometimes other illicit 
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needle covers be explained to patients who are issued 
standard insulin pens during their diabetes education. 
Pharmacists should verify that a patient understands the 
appropriate administration technique whenever pens 
and insulin needles are dispensed, notes the alert, which 
can be viewed at www.nccmerp.org/sites/default/files/ 
nan-20171012.pdf.
FDA Advises on Opioid Addiction 
Medications and Benzodiazepines
Opioid addiction medications – buprenorphine and 
methadone – should not be withheld from patients taking 
benzodiazepines or other drugs that depress the central 
nervous system (CNS), advises FDA. The combined use 
of these drugs increases the risk of serious side effects; 
however, the harm caused by untreated opioid addic-
tion usually outweighs these risks. Careful medication 
management by health care providers can reduce these 
risks, notes a safety alert. FDA is requiring this informa-
tion to be added to the buprenorphine and methadone drug 
labels along with detailed recommendations for minimiz-
ing the use of medication-assisted treatment drugs and 
benzodiazepines together. 
Health care providers should take several actions and 
precautions and should develop a treatment plan when 
buprenorphine or methadone is used in combination 
with benzodiazepines or other CNS depressants. Addi-
tional information may be found at www.fda.gov/Drugs/ 
DrugSafety/ucm575307.htm.
Only About 3% of Pharmacies and Other 
Entities Voluntarily Maintain a Prescription 
Drug Disposal Bin, GAO Reports
In response to the US Senate Judiciary Committee’s 
request to review DEA’s requirements for authorized 
collectors of prescription drugs and participation rates, the 
US Government Accountability Office (GAO) found that 
only about 3% of pharmacies and other entities eligible to 
collect unused prescription drugs for disposal have vol-
unteered to do so. As of April 2017, 2,233 of the 89,550 
eligible entities had registered with DEA to use disposal 
bins to collect unused prescription drugs. The majority 
of the authorized collectors were pharmacies, followed 
by hospitals or clinics. Factors that affected voluntary 
participation in maintaining disposal bins for the public 
included cost, uncertainty of proper implementation, and 
participation in other drug disposal efforts. 
GAO found that participation rates varied by state. 
Connecticut, Missouri, and Maine had the lowest par-
ticipation rates as of April 2017. North Dakota had the 
highest participation rate, followed by Alaska. The report, 
Preventing Drug Abuse: Low Participation by Pharma-
cies and Other Entities as Voluntary Collectors of Unused 
Prescription Drugs, is located on the GAO website at 
www.gao.gov/products/GAO-18-25.
One in Five Drivers Uses a Prescription 
Drug That Can Impair Driving Despite 
Receiving Warnings
A new study that analyzes data from the National Road-
side Survey of Alcohol and Drug Use, 2013-2014, found 
that one in five drivers has taken prescription drugs that 
could impair driving despite having been warned about 
the risks. The authors of the study, “Receipt of Warnings 
Regarding Potentially Impairing Prescription Medications 
and Associated Risk Perceptions in a National Sample 
of U.S. Drivers,” indicate that of the 7,405 random driv-
ers who completed the prescription drug portion of the 
survey, almost 20% reported recent use (within the past 
two days) of a potentially impairing prescription drug. 
Compared to people who were prescribed antidepres-
sants (62.6%) and stimulants (57.7%), those who were 
prescribed sedatives (85.8%) and narcotics (85.1%) were 
most likely to report receiving warnings about the poten-
tial of these drugs to affect driving from their health care 
provider, pharmacy staff, or medication label. 
Several European countries have introduced color-
coded categories (ie, no, minor, moderate, and major 
influence on driving) to drug labeling to increase patient 
safety. Beyond labeling, the authors of the study note 
it is important that health care providers consistently 
communicate with patients about their medications’ 
driving-related risks. The study was published online in 
the Journal of Studies on Alcohol and Drugs on October 
31, 2017, and can be found at https://doi.org/10.15288/
jsad.2017.78.805.
PTCB CPhT Program Earns Accreditation 
From the American National Standards 
Institute
The Pharmacy Technician Certification Board’s 
(PTCB’s) Certified Pharmacy Technician (CPhT) 
Program has earned accreditation from the American 
National Standards Institute (ANSI) Personnel Certifi-
cation Accreditation Program through December 2022. 
ANSI is the first personnel certification accreditation 
body in the US to meet internationally accepted practices 
for accreditation. “We were the first pharmacy techni-
cian certification program to receive accreditation by the 
National Commission for Certifying Agencies (NCCA) 
in 2006, and now we are the first and only program to 
achieve ANSI accreditation,” said PTCB Executive 
Director and Chief Executive Officer William Schimmel 
in a news release. More details are available in PTCB’s 
December 18, 2017 news release, which can be found in 
the News Room section of www.ptcb.org.
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Those technician trainees who are currently employed 
must have received a Board-approved license by July 6, 
2018, in order to continue work in this capacity.
Pharmacy technician trainees hired on or after April 6, 
2018, must obtain a pharmacy technician training license 
before beginning work in a pharmacy.
The application form may be found at https://www.mass 
.gov/pharmacy-technician-licensing. No application fee 
is required.
It is not necessary to receive the physical card before 
beginning work as a technician trainee.
License status may be verified at the Massachusetts 
Health Professions License Verification Site.
Waivers
With the recent update to 247 CMR 14.00 Petition for 
Waiver, waivers now expire five years after original Board 
approval.
All waivers granted by the Board on or before June 30, 
2013, will expire on June 30, 2018. If the waiver continues 
to be necessary, the pharmacist manager of record must 
submit an updated waiver request prior to June 30, 2018, 
for reconsideration. 
All waivers granted after June 30, 2013, will expire five 
years after the date the waiver was initially granted. With-
out additional approval by the Board, a pharmacy must 
comply with all Board regulations after the waiver expires.
Waivers may be approved for any length of time up to 
a maximum of five years. 
Petitions for waiver forms may be found at https://www 
.mass.gov/how-to/petition-for-a-waiver-of-the-provisions-
of-247-cmr.
All documentation of granted waivers must be readily 
retrievable during Board inspections.  
MPJE Study Materials
As a requirement of state licensure, pharmacists must 
pass a law exam. Massachusetts participates in the Mul-
tistate Pharmacy Jurisprudence Examination® (MPJE®) 
developed by the National Association of Boards of 
Pharmacy® (NABP®). The exam consists of 120 multiple-
choice questions with a content blueprint that is the same 
across all participating states. The blueprint, along with a 
breakdown of competencies, is available in the NAPLEX/
MPJE Application Bulletin on the NABP website.
All applicants for licensure as pharmacists are advised 
to review all relevant and current Board regulations and 
policies, Massachusetts Department of Public Health 
regulations, and Massachusetts General Laws to prepare 
for the MPJE. A helpful reference document with related 
website links is available on the Board’s website.
Renovation/Expansion
Pharmacies that are intending to expand or renovate 
must complete and submit an application prior to the 
commencement of any work. The application may be found 
at https://www.mass.gov/files/documents/2018/02/27/
pharmacy-renovation-expansion-request.pdf.
Compounding pharmacies may complete some mi-
nor repairs or service without filing this application. 
Please review the advisory at the following link to help 
make this determination: https://www.mass.gov/files/ 
documents/2018/02/16/repairs-compounding-facilities.pdf.
Reporting Loss of CS – What Is 
‘Significant’?
In Massachusetts, all prescription drugs (Schedules II-
VI) are categorized as CS. Policy 2016-02: Requirements 
and Procedures for Reporting Theft or Loss of Con-
trolled Substances provides guidelines and procedures 
for reporting losses or thefts.
The Board follows DEA’s definition of “significant 
loss” for all CS, including Schedule VI. DEA explains 
that there can be no universal measure as to what quan-
tifies a “significant loss.” What may be significant to 
one pharmacy may not be significant to another (eg, a 
small community pharmacy versus a busy chain phar-
macy). DEA provides details at https://www.deadiversion 
.usdoj.gov/fed_regs/rules/2005/fr0812.htm.
What to Report to the Board – ‘Reportable 
Losses’
 ♦ All losses of any Scheduled II-VI drugs must be re-
ported to the Board when the loss is related to employee 
pilferage/diversion.
 ♦ All significant losses of Schedule II-V drugs due to 
break-in, lost in transit, customer theft, armed robbery, 
or other known or unknown losses must be reported to 
the Board in addition to DEA.
 ♦ All significant losses of Schedule VI drugs that are 
required to be reported to the Massachusetts Prescription 
Awareness Tool (MassPAT), an online tool that is part 
of the Massachusetts Prescription Monitoring Program, 
must be reported to the Board when the loss is due to 
break-in, lost in transit, customer theft, armed robbery, or 
other known or unknown losses. At this time, gabapentin 
is the only Schedule VI drug that must be reported to 
MassPAT.
If a pharmacy has an unreportable loss, document it 
on site in the pharmacy (ie, logbook, electronic log) and 
track for adverse trending. If an adverse trend (eg, three 
losses of the same drug in a 90-day period) is discovered, 
report it to the Board.
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Sterile Compounding Resources
The Board has several advisories and guidance docu-
ments to assist sterile compounders with their responsi-
bilities.
The Advisory on Pharmacy Response to Failed 
HEPA Filters in ISO-Classified Environments provides 
guidance regarding proper response and remediation of 
high-efficiency particulate air (HEPA) filter failures in 
ISO-classified environments. The advisory provides re-
mediation steps and encourages pharmacies to perform 
risk assessments of the products that were compounded 
during the time of failure. It also provides guidance on 
how to proceed with continuation of compounding during 
the remediation period. 
The Advisory on Conducting Repairs or Service to 
Sterile Compounding Facilities or Facilities Engaging in 
Complex Non-Sterile Compounding provides guidance 
and examples of when such facilities may conduct repairs 
and/or service without having to submit an Application 
for Remodeling, Change in Configuration, or Change 
in Square Footage (Renovation/Expansion).
Repairs and services that fall outside of the scope of 
the advisory require submission of an Application for 
Remodeling, Change in Configuration, or Change in Square 
Footage (Renovation/Expansion).
The Board advises suspension of compounding activities 
during and/or after any service or construction until envi-
ronmental monitoring reports demonstrate levels within 
acceptable United States Pharmacopeia Chapter <797> 
levels. As with failed HEPA filters, the pharmacy is re-
sponsible for ensuring continuity of care for patients in 
the event of suspended compounding services and should 
utilize a risk assessment to determine when it is safe to 
resume compounding.
If compounding activity is not suspended, the Board ad-
vises limited beyond-use dates and not freezing or batching 
any compounded sterile preparations.
While any service or work is in progress, the facility must 
have a written strategy to mitigate the effects of the work 
(eg, excess dust and particulates) and explain how quality 
assurance will be maintained during the work period. All 
reports and documentation related to the repair or service 
event must be maintained in the pharmacy’s records and 
available for Board inspection.
In addition to these advisories, the Board has also pro-
vided guidance documents such as Recommended Phar-
macy Response to Above Action Level Environmental 
Monitoring Results and Remediation Considerations 
for Handling Above Action Level Environmental Moni-
toring (EM) Results. These tools can help pharmacies 
ascertain the root cause of an above action level result as 
well as how to proceed with a plan to remediate.
Did You Know?
 ♦ All pharmacies that compound, including those that only 
prepare simple nonsterile preparations, must maintain a 
defective drug preparation log. Defective drug prepara-
tions are those that demonstrate any out of specification 
result such as potency, purity, quality, stability, improper 
composition, contamination, mislabeling, or sterility. 
Please review the advisory at the following link for 
details: https://www.mass.gov/advisory/advisory-on-
pharmacy-requirement-to-maintain-defective-drug-
preparation-log.
 ♦ You can perform a self-inspection of your pharmacy using 
the same tools the pharmacy inspectors use. These tools 
may all be found under “Inspection Templates” at https://
www.mass.gov/lists/pharmacy-practice-resources.
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